CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in Tübingen, Germany.
IPO Year: 2020
Exchange: NASDAQ
Website: curevac.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/25/2024 | $12.00 → $4.00 | Outperform → Market Perform | Leerink Partners |
| 6/8/2023 | $13.00 | Outperform | SVB Securities |
| 1/19/2023 | $8.00 → $18.00 | Neutral → Buy | UBS |
| 1/9/2023 | $9.00 → $21.00 | Hold → Buy | Jefferies |
| 1/21/2022 | $55.00 → $20.00 | Neutral → Underperform | B of A Securities |
| 1/18/2022 | $52.00 | Market Outperform | JMP Securities |
| 10/22/2021 | $35.00 | Hold | Deutsche Bank |
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter€400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNONew off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1 in H2 2025New preclinical prophylactic vaccine program for urinary tract infections initiated, supported by positive preclinical data versus protein-based vaccinesPositive Phase 2 data from seasonal influen
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter and first nine months 2024 on Tuesday, November 12, 2024. The company will host a conference call and webcast on the same day at3 p.m. CET / 9 a.m. EST.Dial-in numbers to participate in the conference call:U.S. Toll-Free: +1-877-407-0989International: +1-201-389-0921Germany: 0800-182-0040 (landline access) / 0800-184-4713 (cell phone access)The live webcast link can be accesse
Experienced CFO and investment banker with 30-year track record will help drive CureVac's transformationTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment of Axel Sven Malkomes as Chief Financial Officer, effective November 11, 2024.Mr. Malkomes joins CureVac at a pivotal moment as the company enters a new chapter of growth and innovation, bringing over three decades of senior corporate and investment banking experience within the biotech and pharmaceutical industries."Axel's
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that new and updated data will be shared in two oral presentations and four posters at the 12th International mRNA Health Conference, taking place in Boston, Massachusetts, November 12-14, 2024.More detailed preliminary safety, tolerability and immunogenicity data from the dose escalation part of CureVac's ongoing Phase 1 CVGBM cancer vaccine study in patients with resected glioblastoma will be shared in an oral presentation. Initial data fr
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced poster presentations at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place November 8-10 in Houston, USA.CureVac will present, among other data, extended preliminary immunogenicity results from Part A of the dose escalation phase of its ongoing Phase 1 CVGBM cancer vaccine study in patients with resected glioblastoma. The presentation will expand on safety, tolerability and immunogenicity results of the CVGBM tr
Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy84% of immune responses were de novo, observed in patients without pre-existingT-cell activity against encoded cancer antigensCVGBM was generally well tolerated up to the highest tested dose level of 100 µg with no dose-limiting toxicitiesMost common adverse events were mild to moderate systemic reactions such as headache, fever and chills, which resolved within 1-2 days post injection100 µg was selected as the recommended dose for the dose expansion phase, which recently started enrollmentTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE /
Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpointsVaccine candidate based on CureVac's proprietary second-generation mRNA backboneGSK confirmed data support advancing program to Phase 3; dosing of first Phase 3 participant is associated with a significant milestone payment for CureVacIn July 2024, GSK assumed full control for the development, manufacturing and commercialization of influenza vaccines through new licensing agreementTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 12, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 9, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the first clinical data from CureVac's ongoing Phase 1 CVGBM cancer vaccine study in patients with resected glioblastoma will be presented at the European Society for Medical Oncology (ESMO) Congress (Barcelona, Spain, September 13-17, 2024). Clinical data will be presented as an oral presentation on Friday, September 13, along with a poster presentation of preclinical data supporting the program's development."Cancer vaccines have tre
Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's mRNA platformInitiated strategic workforce reduction of ~30% by end of 2024, optimizing business to focus on high-value opportunities in oncology, infectious diseases and other areasInvoiced €10 million milestone payment after Phase 2 transition of pre-pandemic avian influenza (H5N1) program; candidate fully licensed to GSK under new agreementDosing of first patient in Phase 1 study Part B in glioblastoma with CVGBM to establish dose-confirmation; initial dose-escalation Part A data accepted for oral presentation at ESMOStrengthening of Supervisory Board
First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBMPart B expected to include up to 20 patients to generate extended data on safety, tolerability, and immunogenicity of CVGBM TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the start of the dose-confirmation Part B of its ongoing Phase 1 study in patients with resected glioblastoma. CVGBM is CureVac's first investigational cancer vaccine based on its proprietar
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter€400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNONew off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1 in H2 2025New preclinical prophylactic vaccine program for urinary tract infections initiated, supported by positive preclinical data versus protein-based vaccinesPositive Phase 2 data from seasonal influen
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter and first nine months 2024 on Tuesday, November 12, 2024. The company will host a conference call and webcast on the same day at3 p.m. CET / 9 a.m. EST.Dial-in numbers to participate in the conference call:U.S. Toll-Free: +1-877-407-0989International: +1-201-389-0921Germany: 0800-182-0040 (landline access) / 0800-184-4713 (cell phone access)The live webcast link can be accesse
Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's mRNA platformInitiated strategic workforce reduction of ~30% by end of 2024, optimizing business to focus on high-value opportunities in oncology, infectious diseases and other areasInvoiced €10 million milestone payment after Phase 2 transition of pre-pandemic avian influenza (H5N1) program; candidate fully licensed to GSK under new agreementDosing of first patient in Phase 1 study Part B in glioblastoma with CVGBM to establish dose-confirmation; initial dose-escalation Part A data accepted for oral presentation at ESMOStrengthening of Supervisory Board
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinationsCureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replacedLONDON, UK, TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and focus their respective mRNA
Organizational redesign on track, trimming residual pandemic infrastructure and reducing 150 positions by year endU.S. FDA Fast Track designation granted for pre-pandemic avian influenza (H5N1) vaccine currently in Phase 1 development; candidate jointly developed with GSKSettlement with Acuitas Therapeutics includes acknowledgment of CureVac's ownership of certain patent claims and Acuitas's licenses to selected patentsContinuation of U.S. patent litigation against Pfizer/BioNTech with trial expected to begin in Q2 2025; litigation continues under seven U.S. patents with three patents to be withdrawn due to out-licensing to Acuitas TherapeuticsProgress in German patent litigation against Pfi
Organizational redesign and rightsizing initiated across company to streamline structures, increase efficiency and reduce operating costsTogether with GSK, ended Pandemic Preparedness Agreement (PPA) with Federal Republic of Germany, after consultation with the German Federal Ministry of Health Cash and cash equivalents position of €402.5 million as of December 31, 2023; cash runway extended into Q4 2025 with organizational redesign and despite PPA wind-downStrategic collaboration signed with world-leading oncology center MD Anderson, creating unique expertise to jointly discover and develop novel cancer vaccinesAppointment of Thaminda Ramanayake as Chief Business Officer, bringing more than
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business UpdateEnrollment completed for Phase 2 COVID-19 study with mono- and bivalent vaccine candidates; study on track for data read-out in early 2024First participant dosed in seasonal flu Phase 2 study with potentially differentiated multivalent candidate; €15 million milestone payment by GSK triggeredPhase 1 study in glioblastoma well on track with opening of third dose level for CVGBM, CureVac's multiepitope cancer vaccine candidatePreclinical data with multiepitope construct in oncology shows strong T cells responses and significantly extended survival in checkpoint-inhibitor resistan
Initiated Phase 2 study in COVID-19 with monovalent and bivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSKInitiated Phase 1 study of cancer vaccine candidate, CVGBM, for surgically resected glioblastoma; recruitment of second dose cohort well on trackBroadened position in patent litigations by expanding the scope and asserting new intellectual property rights in Germany and the U.S.Public hearing held before the Regional Court Düsseldorf as part of German patent litigation against Pfizer/BioNTechCash and cash equivalents position of €537.9 million as of June 30, 2023TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE
Continued technology platform validation with extended preliminary data from older adults in ongoing Phase 1 studies in COVID-19 and fluCOVID-19: monovalent modified mRNA construct CV0501 successfully boosted antibody titers against BA.1 and ancestral variants in adults age ≥65Flu: monovalent modified mRNA construct Flu-SV-mRNA elicited antibodies approximately 2.3 times those of licensed vaccine comparator in adults aged 60-80Reaffirming plan to advance modified mRNA COVID-19 and flu candidates to the next stages of clinical development in collaboration with GSK in 2023TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 30, 2023 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical c
Promising COVID-19 and flu modified mRNA vaccine candidates identified based on positive preliminary data from ongoing Phase 1 studiesAll candidates use CureVac's advanced second-generation mRNA backbone optimized to achieve improved mRNA translation and strong immune responses at low dosesThe preliminary results provide strong evidence of technology for CureVac's mRNA platform; CureVac and partner GSK plan to advance modified mRNA COVID-19 and flu candidates to the next stages of clinical developmentCOVID-19: monovalent modified mRNA vaccine candidate CV0501, encoding Omicron variant BA.1, successfully boosted antibody titers against BA.1 and the wild type variants and was generally well to
Leerink Partners downgraded CureVac from Outperform to Market Perform and set a new price target of $4.00 from $12.00 previously
SVB Securities initiated coverage of CureVac with a rating of Outperform and set a new price target of $13.00
UBS upgraded CureVac from Neutral to Buy and set a new price target of $18.00 from $8.00 previously
Jefferies upgraded CureVac from Hold to Buy and set a new price target of $21.00 from $9.00 previously
B of A Securities downgraded CureVac from Neutral to Underperform and set a new price target of $20.00 from $55.00 previously
JMP Securities initiated coverage of CureVac with a rating of Market Outperform and set a new price target of $52.00
Deutsche Bank initiated coverage of CureVac with a rating of Hold and set a new price target of $35.00
B of A Securities downgraded CureVac from Buy to Neutral and set a new price target of $50.00
Credit Suisse resumed coverage of CureVac with a rating of Underperform
Guggenheim initiated coverage of CureVac with a rating of Neutral
SC 13G/A - CureVac N.V. (0001809122) (Subject)
SC 13G/A - CureVac N.V. (0001809122) (Subject)
SC 13G - CureVac N.V. (0001809122) (Subject)
SC 13D/A - CureVac N.V. (0001809122) (Subject)
SC 13D/A - CureVac N.V. (0001809122) (Subject)
SC 13D/A - CureVac N.V. (0001809122) (Subject)
SC 13D/A - CureVac N.V. (0001809122) (Subject)
SC 13D/A - CureVac N.V. (0001809122) (Subject)
SC 13D/A - CureVac N.V. (0001809122) (Subject)
SC 13D/A - CureVac N.V. (0001809122) (Subject)
6-K - CureVac N.V. (0001809122) (Filer)
6-K - CureVac N.V. (0001809122) (Filer)
6-K - CureVac N.V. (0001809122) (Filer)
6-K - CureVac N.V. (0001809122) (Filer)
20-F - CureVac N.V. (0001809122) (Filer)
6-K - CureVac N.V. (0001809122) (Filer)
6-K - CureVac N.V. (0001809122) (Filer)
6-K - CureVac N.V. (0001809122) (Filer)
144 - CureVac N.V. (0001809122) (Subject)
144 - CureVac N.V. (0001809122) (Subject)
Experienced CFO and investment banker with 30-year track record will help drive CureVac's transformationTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment of Axel Sven Malkomes as Chief Financial Officer, effective November 11, 2024.Mr. Malkomes joins CureVac at a pivotal moment as the company enters a new chapter of growth and innovation, bringing over three decades of senior corporate and investment banking experience within the biotech and pharmaceutical industries."Axel's
Agomab Therapeutics NV (‘Agomab') today announced that Pierre Kemula will join the company as Chief Financial Officer (CFO) effective November 1, 2024, bringing more than 15 years of experience in global biotech financial leadership. Mr. Kemula joins Agomab from CureVac N.V. (NASDAQ:CVAC), where he currently serves as CFO. In this role, Mr. Kemula has led CureVac's financial and capital markets activities since 2016, characterized by a successful listing on Nasdaq and two subsequent follow-on offerings. Under his leadership, CureVac raised over $1.6 billion in equity. Mr. Kemula will succeed Tolga Hassan, who has recently left the company to explore new opportunities closer to home. Follo
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 24, 2024 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the voting results of the Company's annual general meeting.The shareholders of the Company voted in favor of all proposals. These proposals included the appointment of Thaminda Ramanayake and the reappointment of Malte Greune as members of the Management Board, both effective June 24th, 2024. Additionally, Jean Stéphenne and Mathias Hothum were reappointed as members of the supervisory board, Birgit Hofmann was appointed as a new member of t
Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-makingStrong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areasTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 24, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that Thaminda Ramanayake has been appointed to the role of Chief Business Officer, effective June 1, 2024."Thaminda's extensive experience in advancing corporate strategy, business develo
Former CureVac Chief Scientific Officer to Lead Research & Development of CNS Disease Therapies Yarrow Biotechnology, Inc. ("Yarrow"), an RTW Investments, LP ("RTW") -incubated company developing nucleic acid therapeutics and other modalities for severe, genetically defined diseases including those of the central nervous system ("CNS"), today announced the appointment of Dr. Igor Splawski as Chief Scientific Officer. Dr. Splawski was previously the Chief Scientific Officer and a member of the Executive Board of CureVac (NASDAQ:CVAC), where he led a team of 150 scientists developing mRNA technology and mRNA vaccines and therapeutics for infectious disease, cancer, and rare indications. Th
Dr. Franz-Werner Haas to complete successful tenure as CEO by March 31, 2023Dr. Alexander Zehnder to succeed Dr. Haas as new CEO, joining from Sanofi onApril 1, 2023TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 9, 2023 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that after more than 10 years as a member of the CureVac management board and three years as CEO, Dr. Franz Haas will step down as CEO, effective March 31, 2023. Dr. Alexander Zehnder will succeed Dr. Haas, joining from Sanofi on April 1, 2023."The recent clinical validation of the power of C
BERLIN, GERMANY / ACCESSWIRE / January 13, 2022 / Today dievini and the Federal Republic of Germany announced the signing of a supplement to the shareholders' agreement between Kreditanstalt für Wiederaufbau (KfW) and the investment company dievini Hopp BioTech holding GmbH & Co. KG (dievini), DH-LT-Investments GmbH, and Dietmar Hopp related to their common shares in CureVac N.V. (CureVac) (NASDAQ:CVAC). The shareholders' agreement was originally signed on 16 June 2020. It governs, among other things, the voting behavior of the shareholders, the appointment of members to the Supervisory Board of CureVac, and certain holding periods and rights of first offer mechanisms for CureVac common shar